{"paper_id":"e6b26931-59ce-4b1c-b0ba-84b8fc4017d2","body_text":"ABSTRACT\nObjective\nThis study aimed to investigate the curative effect of motherwort combined with ethinylestradiol-cyproterone acetate (EE/CPA) on dysfunctional uterine bleeding (DUB).\nMethods\nAtotal of 68 patients with DUB were divided into a single medication group (treated with EE/CPA) and a combination medication group(treated with motherwort and EE/CPA). The clinical efficacy, uterine hemodynamic parameters, sex hormone levels, coagulation index levels, blood routine test levels, and adverse reactions of patients were evaluated.\nResults\nAfter three months of treatment, total treatment response rate of the combination medication group was significantly higher than that of the single medication group. Decreased uterine volume, endometrial thickness and resistance index (RI), increased pulsatility index(PI), average flow rate, and uterine artery blood flow, as well asreduced follicle-stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (P), activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen (FIB), thrombin time(TT), platelet count (PLT), red blood cell (RBC), and hemoglobin (Hb)levels were witnessed in patients of the two groups. In thecombination medication group, there exhibited reduced uterine volume, endometrial thickness and RI, elevated PI, average flow rate, and uterine artery blood flow, reduced P, E2, FSH, LH, aPTT, PT, FIB, TT,PLT, RBC, and Hb levels in comparison to the single medication group.\nConclusion\nThe combination of motherwort and EE/CPA is clinically effective in the treatment of DUB.\nDeclaration of interest\nThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.\nReviewer disclosures\nPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.\nAuthor contributions\nQ Tang contributed to the study design. X Chen contributed to the manuscript editing. Q Tang and X Chen contributed to the experimental studies and data analysis. All authors have read and have approved the final manuscript.\nEthical approval\nThe work has been approved by the ethics committee of the Traditional Chinese Medical Hospital of Yongkang (approval number: 20200125) with written informed consent obtained from all participants.\nSupplementary material\nSupplemental data for this article can be accessed online at https://doi.org/10.1080/17474086.2024.2343878","source_license":"CC0","license_restricted":false}